The development of checkpoint inhibitor therapies is undoubtedly a major advance in cancer treatment. But first, these drugs must undergo extensive clinical research, which requires precision, efficacy, and speed before they reach the doctor’s office. It’s time for a broader approach – artificial intelligence powered biomarker analysis for immune profiling.  ..read more

Dr. Ralf Huss, Chief Medical Officer at Definiens, explains how the innovative combination of artificial intelligence (AI) and expert knowledge is critical for driving the successful adoption of digital solutions in cancer research.  ..read more

2018 will be remembered as a decisive year for immuno-oncology. In particular, Nobel Prize winners James Allison of MD Anderson Cancer Center in Houston, Texas, and Tasuku Honjo of Kyoto University in Japan lifted the field of immunotherapy to international recognition for those outside the scientific and medical communities. For the patient, these new alternatives to standard oncology therapies offer new hope for life-extending treatments using immunotherapy ..read more

Personalized medicine aims at bringing the right drug to the right patient at the right time. Getting many things right at the same time is challenging. There are many potential treatments for cancer patients and many of these can be combined with each other resulting in a lot of potential combination treatments. This growing number of treatment options makes it increasingly difficult to determine the right one for an individual patient. Biomarkers that help to predict response to a treatment are highly needed to guide treatment selection to maximize efficiency for both patients and payers ..read more

The development of checkpoint inhibitor therapies is undoubtedly a major advance in cancer treatment. But first, these drugs must undergo extensive clinical research, which requires precision, efficacy, and speed before they reach the doctor’s office. It’s time for a broader approach – artificial intelligence powered biomarker analysis for immune profiling ..read more

The introduction of checkpoint inhibitors in clinical oncology has transformed the way we treat cancer patients. Currently, observed sustained clinical responses have given patients new hope. And yet, these treatments don’t provoke the exact immune response in every patient. The big question is of course, ‘why?’. We asked Dr. Monika Baehner to shed some light on how AI-powered tissue analysis is helping change precision oncology to treat patients better with targeted therapies ..read more

Artificial Intelligence (AI) has an enormous computational power to process large, complex quantities of data. And yet, to harness this power, seasoned and astute computer scientists must leverage both their knowledge and experience to apply the right techniques for the best results every time ..read more

Dr. Ralf Huss, Chief Medical Officer at Definiens, explains how the innovative combination of artificial intelligence (AI) and expert knowledge is critical for driving the successful adoption of digital solutions in cancer research ..read more

This article originally appeared on Global Exchange before Digital Pathology & AI Congress in London 2018 ..read more